# Assessment of β-Thalassemia Trait Occurrence in an Outpatient Sample from Southern Chile: A Retrospective Study

**Authors:** Mario Balcázar-Villarroel, Angélica Mancilla-Uribe, Sandra Navia-León, Luis Carrasco-Fajardin, Johana Bohle-Matamala, Cristian Calbucura-Ovalle, Francisco Torrens, Eduardo Carmine-Peña, Cristian Sandoval, Francisca Peña

PMC · DOI: 10.3390/diagnostics15212759 · 2025-10-31

## TL;DR

This study estimates the frequency of β-thalassemia trait in southern Chile and highlights its importance in diagnosing microcytic anemia.

## Contribution

The study provides the first recent estimate of β-thalassemia trait frequency in southern Chile using clinical laboratory data.

## Key findings

- The frequency of β-thalassemia trait was 0.24% among 24,634 reviewed patients.
- The frequency is higher than previous Chilean estimates but lower than in some South American countries.
- β-thalassemia trait should be considered in the differential diagnosis of microcytic anemia in Chile.

## Abstract

Background/Objectives: Thalassemia comprises a group of heterogeneous hereditary hemoglobinopathies characterized by impaired hemoglobin synthesis due to mutations in the α, β, and/or δ globin genes. The resulting ineffective erythropoiesis produces anemia of variable severity depending on the affected globin chain. Although β-thalassemia is most prevalent in the Mediterranean region, the Middle East, and Southeast Asia, migration has contributed to its global spread, including in non-endemic areas. In Chile, published data on β-thalassemia trait (BTT) and β-thalassemia major (BTM) remain scarce. This study aimed to estimate the frequency of BTT in referred outpatients to a clinical laboratory in southern Chile. Methods: A retrospective observational study was conducted between January 2021 and November 2024 at a clinical laboratory in Puerto Montt. Complete Blood Cell counts (CBCs) from unique patients were reviewed, and those confirmed with confirmed thalassemia (HbA2 > 3.5%) were selected. Results: During the study period, 24,634 CBCs were reviewed. Sixty patients were confirmed as carriers of BTT, corresponding to a frequency of 0.24% (CI 95%: 0.18–0.31%) in the referred outpatients to laboratory (60/24,634). This occurrence is higher than the only previously published Chilean estimate but lower than frequencies reported in several South American countries. Conclusions: This investigation demonstrates a relatively low but non-negligible frequency of BTT in outpatients from southern Chile. The findings emphasize the importance of considering BTT in the differential diagnosis of microcytic anemia, a condition often underestimated in routine practice. Broader multicenter studies across Chile are warranted to validate these results and to provide a clearer picture of the epidemiology of β-thalassemia in the country.

## Linked entities

- **Diseases:** microcytic anemia (MONDO:0001245)

## Full-text entities

- **Genes:** HBA2 (hemoglobin subunit alpha 2) [NCBI Gene 3040] {aka ECYT7, HBA-T2, HBH}
- **Diseases:** anemia (MESH:D000740), Thalassemia (MESH:D013789), CBCs (MESH:C562567), hereditary hemoglobinopathies (MESH:D009386), beta-Thalassemia (MESH:D017086), impaired hemoglobin synthesis (MESH:D006445), microcytic anemia (MESH:C536357)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12609962/full.md

---
Source: https://tomesphere.com/paper/PMC12609962